Regulation of the Tumor Suppressor PTEN through Exosomes: A Diagnostic Potential for Prostate Cancer

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Gabriel, Kathleen ^a,b   Ingram, Alistair ^a,b   Austin, Richard ^a,b   Kapoor, Anil ^a   Tang, Damu ^a,b   Majeed, Fadwa ^a,b   Qureshi, Talha ^a,b   Al Nedawi, Khalid ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CANCER PATIENT; EXOSOME; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY MECHANISM;

AGED; CASE-CONTROL STUDIES; CELL LINE, TUMOR; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880823162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070047     Document Type: Article

References (44)

1. Crawford ED, Andriole GL, Marberger M, Rittmaster RS, (2010) Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology 75: 502-509.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics 2009. CA: a cancer journal for clinicians 59: 225-249.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA: a cancer journal for clinicians 57: 43-66.
4. Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, et al. (2009) PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU international 104: 556-561.
5. Di Cristofano A, Pandolfi PP, (2000) The multiple roles of PTEN in tumor suppression. Cell 100: 387-390.
6. Maccario H, Perera NM, Davidson L, Downes CP, Leslie NR, (2007) PTEN is destabilized by phosphorylation on Thr366. The Biochemical journal 405: 439-444.
7. Parsons R, (2004) Human cancer, PTEN and the PI-3 kinase pathway. Seminars in cell & developmental biology 15: 171-176.
8. Salmena L, Carracedo A, Pandolfi PP, (2008) Tenets of PTEN tumor suppression. Cell 133: 403-414.
9. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, et al. (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proceedings of the National Academy of Sciences of the United States of America 95: 5246-5250.
10. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, et al. (2004) PTEN promoter is methylated in a proportion of invasive breast cancers. International journal of cancer Journal international du cancer 112: 407-410.
11. Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, et al. (2004) Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. International journal of oncology 25: 1615-1623.
12. He L, Ingram A, Rybak AP, Tang D, (2010) Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. The Journal of clinical investigation 120: 2094-2108.
13. Mathivanan S, Ji H, Simpson RJ, (2010) Exosomes: extracellular organelles important in intercellular communication. Journal of proteomics 73: 1907-1920.
14. Nieuwland R, Sturk A, (2010) Why do cells release vesicles? Thrombosis research 125Suppl 1: S49-51.
15. Al-Nedawi K, Meehan B, Rak J, (2009) Microvesicles: messengers and mediators of tumor progression. Cell Cycle 8: 2014-2018.
16. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C, (2010) Microvesicles: mediators of extracellular communication during cancer progression. Journal of cell science 123: 1603-1611.
17. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J, (2009) Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proceedings of the National Academy of Sciences of the United States of America 106: 3794-3799.
18. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, et al. (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature cell biology 10: 619-624.
19. Duijvesz D, Luider T, Bangma CH, Jenster G, (2011) Exosomes as biomarker treasure chests for prostate cancer. European urology 59: 823-831.
20. Halvorsen OJ, Haukaas SA, Akslen LA, (2003) Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 9: 1474-1479.
21. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, et al. (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer research 59: 4291-4296.
22. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, et al. (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer research 58: 204-209.
23. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, et al. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. The New England journal of medicine 317: 909-916.
24. Tosoian J, Loeb S, (2010) PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. TheScientificWorldJournal 10: 1919-1931.
25. De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G, (2010) Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR-BTR 93: 62-70.
26. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD, (2004) Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 119: 174-186.
27. Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, et al. (2009) A systematic review of the diagnostic accuracy of prostate specific antigen. BMC urology 9: 14.
28. Al-Nedawi K, Szemraj J, Cierniewski CS, (2005) Mast cell-derived exosomes activate endothelial cells to secrete plasminogen activator inhibitor type 1. Arteriosclerosis, thrombosis, and vascular biology 25: 1744-1749.
29. Putz U, Howitt J, Doan A, Goh CP, Low LH, et al. (2012) The Tumor Suppressor PTEN Is Exported in Exosomes and Has Phosphatase Activity in Recipient Cells. Science signaling 5: ra70.
30. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, et al. (2009) A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proceedings of the National Academy of Sciences of the United States of America 106: 480-485.
31. Ross AH, Gericke A, (2009) Phosphorylation keeps PTEN phosphatase closed for business. Proceedings of the National Academy of Sciences of the United States of America 106: 1297-1298.
32. Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, et al. (2008) Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell death and differentiation 15: 1723-1733.
33. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, et al. (2001) PTEN controls tumor-induced angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 98: 4622-4627.
34. Chu IM, Hengst L, Slingerland JM, (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature reviews Cancer 8: 253-267.
35. Weng LP, Brown JL, Eng C, (2001) PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Human molecular genetics 10: 599-604.
36. Wurm FM, Hacker D, (2011) First CHO genome. Nature biotechnology 29: 718-720.
37. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP, (1998) Pten is essential for embryonic development and tumour suppression. Nature genetics 19: 348-355.
38. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
39. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL, (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United States of America 95: 15587-15591.
40. Collino F, Deregibus MC, Bruno S, Sterpone L, Aghemo G, et al. (2010) Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PloS one 5: e11803.
41. Sawyers CL, (2008) The cancer biomarker problem. Nature 452: 548-552.
42. Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, et al. (2009) Can urinary exosomes act as treatment response markers in prostate cancer? Journal of translational medicine 7: 4.
43. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, et al. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA: the journal of the American Medical Association 279: 1542-1547.
44. Nagy JA, Dvorak HF (2012) Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clinical & experimental metastasis.